Imminent top line data from the BTX 1801 study is keenly awaited, with the results likely to drive sharp share price moves in either direction depending on the outcome. Success here would highlight its potential as a new treatment for resistant bacteria.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.